About
Pipeline & Research
NEWS & MEDIA
Investors
Careers
Contact Us

Select Page

BeyondSpring PROTECTIVE-2 Phase 3 Trial Topline Results Update

November 17, 2020

11.16.2020

BeyondSpring PROTECTIVE-2 Phase 3 Trial Topline Results Update

View webcast

Search for:

RECENT NEWS ARTICLES

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors
BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

RECENT MEDIA COVERAGE

TD Ameritrade Watch List
Managing Chemotherapy Toxicities for Improved Patient Outcomes
New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction
Seed Therapeutics blossoms in an $800M deal with Lilly
Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
Pegfilgrastim Plus Plinabulin Reduces Chemo-Induced Neutropenia in TAC-Treated Patients
Dr. Lan Huang Featured in Nature Titled “‘Innovation’ Nation”
Woman of the Week Podcast: Dr. Lan Huang, Co-founder, Chairman and Chief Executive Officer BeyondSpring

Investor Contact
IR@beyondspringpharma.com

Media Contact
PR@beyondspringpharma.com

BeyondSpring Inc.
+1 (646) 305-6387
general@beyondspringpharma.com

Who We Are
Management Team
Scientific Advisors
Board of Directors

PIPELINE & RESEARCH

Pipeline Overview
Plinabulin
Protein Degradation
Other Pipeline
Posters & Publications
Collaboration
Expanded Access Policy

Stock Overview
Events & Presentations
Financials & Filings
Corporate Governance

Job Opportunities

NEWS & MEDIA

Press Releases
Media Coverage

BeyondSprings Inc LinkedIn

BeyondSprings Inc Twitter

©2021 BeyondSpring Inc. All rights reserved. Privacy Notice | Terms of Use

We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.Ok Privacy policy